Objective : Escherichia coli is one of the most common pathogens causing infection in the world. E. coli strains can leadto emergent community- and hospital -acquired infections.Treatment of ESBL producing E. coli infections encounterdifficulties due to the resistance which is easily acquired.Treatment options may decrease particularly in the strainsproducing expended -spectrum beta -lactamase (ESBL). R esearchers continue to search for an alternative due to thelimited treatment options. Tigecycline (GAR -936), a derivative of glycylcycline, is an agent accepted for the usage fortreatment in recent years. In this study, it was aimed toinvestigate the in vitro susceptibility rate of ESBL producingE. coli strains isolated from various clinical specimens inmicrobiology laboratory of Abant Izzet Baysal UniversityFaculty of Medicine to tigecycline. Method : Minimum inhibitory concentration (MIC) of tigecycline were detemined with broth microdilution method for atotal of 100 ESBL producing E. coli isolates. Results : MIC values of tigecycline to the isolates were foundbetween a range of 0.125 -4 µg/ml, according to this 97(97%) of the isolates were determined as susceptible and 3(3%) were found as intermediate to tigecycline. The MIC50value was found 0.5 µg/ml and MIC90 was 2 µg/ml. Conclusion : The findings obtained from our study showsthat tigecycline is still an appropriate alternative in trea tment of infections caused by ESBL producing E. coli in ourhospital.